Targeting STAT3 Signaling in Kidney Disease

Overview

Journal Am J Physiol Renal Physiol

Publisher American Physiological Society

Specialties Nephrology
Physiology

Date 2019 Apr 4

PMID 30943069

Citations 39

Authors

Jesse Pace

Praharshasai Paladugu

Bhaskar Das

John C He

Sandeep K Mallipattu

Affiliations

Soon will be listed here.

Abstract

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is a multifaceted transduction system that regulates cellular responses to incoming signaling ligands. STAT3 is a central member of the JAK/STAT signaling cascade and has long been recognized for its increased transcriptional activity in cancers and autoimmune disorders but has only recently been in the spotlight for its role in the progression of kidney disease. Although genetic knockout and manipulation studies have demonstrated the salutary benefits of inhibiting STAT3 activity in several kidney disease models, pharmacological inhibition has yet to make it to the clinical forefront. In recent years, significant effort has been aimed at suppressing STAT3 activation for treatment of cancers, which has led to the development of a wide variety of STAT3 inhibitors, but only a handful have been tested in kidney disease models. Here, we review the detrimental role of dysregulated STAT3 activation in a variety of kidney diseases and the current progress in the treatment of kidney diseases with pharmacological inhibition of STAT3 activity.

Citing Articles

gdf11 is required for pronephros/cloaca development through targeting TGF-β signaling.

Tian X, Yao W, Tan J, Hu Z, Liu J Sci Rep. 2025; 15(1):8052.

PMID: 40055488 PMC: 11889093. DOI: 10.1038/s41598-025-92571-y.

Canagliflozin alleviates acetaminophen-induced renal and hepatic injury in mice by modulating the p-GSK3β/Fyn-kinase/Nrf-2 and p-AMPK-α/STAT-3/SOCS-3 pathways.

Bishr A, El-Mokadem B, Gomaa A Sci Rep. 2025; 15(1):729.

PMID: 39753621 PMC: 11699121. DOI: 10.1038/s41598-024-82163-7.

Gut Dysbiosis and Probiotic Therapy in Chronic Kidney Disease: A Comprehensive Review.

Ribeiro F, de Luna Freire M, de Oliveira Coutinho D, de Santana Cirilo M, Alves J Probiotics Antimicrob Proteins. 2024; .

PMID: 39668321 DOI: 10.1007/s12602-024-10427-9.

STAT3 Protein-Protein Interaction Analysis Finds P300 as a Regulator of STAT3 and Histone 3 Lysine 27 Acetylation in Pericytes.

Kundu G, Ghasemi M, Yim S, Rohil A, Xin C, Ren L Biomedicines. 2024; 12(9).

PMID: 39335615 PMC: 11428717. DOI: 10.3390/biomedicines12092102.

Transcriptome meta-analysis and validation to discovery of hub genes and pathways in focal and segmental glomerulosclerosis.

Roointan A, Ghaeidamini M, Yavari P, Naimi A, Gheisari Y, Gholaminejad A BMC Nephrol. 2024; 25(1):293.

PMID: 39232654 PMC: 11375834. DOI: 10.1186/s12882-024-03734-4.

References

Zhang X, Yue P, Page B, Li T, Zhao W, Namanja A . Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A. 2012; 109(24):9623-8. PMC: 3386073. DOI: 10.1073/pnas.1121606109. View

Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K . STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med. 1999; 189(1):63-73. PMC: 1887683. DOI: 10.1084/jem.189.1.63. View

Huang W, Dong Z, Chen Y, Wang F, Wang C, Peng H . Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene. 2015; 35(6):783-92. DOI: 10.1038/onc.2015.215. View

Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J . AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015; 7(314):314ra185. PMC: 5279222. DOI: 10.1126/scitranslmed.aac5272. View

Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E . IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol. 2008; 19(6):1106-15. PMC: 2396933. DOI: 10.1681/ASN.2007070744. View

Okumura F, Okumura A, Matsumoto M, Nakayama K, Hatakeyama S . TRIM8 regulates Nanog via Hsp90β-mediated nuclear translocation of STAT3 in embryonic stem cells. Biochim Biophys Acta. 2011; 1813(10):1784-92. DOI: 10.1016/j.bbamcr.2011.05.013. View

Estrada C, Paladugu P, Guo Y, Pace J, Revelo M, Salant D . Krüppel-like factor 4 is a negative regulator of STAT3-induced glomerular epithelial cell proliferation. JCI Insight. 2018; 3(12). PMC: 6124441. DOI: 10.1172/jci.insight.98214. View

Yu J, Wu H, Liu Z, Zhu Q, Shan C, Zhang K . Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2/STAT3 pathway activation. Int J Mol Med. 2017; 40(4):1185-1193. PMC: 5593472. DOI: 10.3892/ijmm.2017.3098. View

Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M . The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017; 15(1):23. PMC: 5480189. DOI: 10.1186/s12964-017-0177-y. View

10.

Xu M, Feng D, Wang H, Guan Y, Yan X, Gao B . IL-22 ameliorates renal ischemia-reperfusion injury by targeting proximal tubule epithelium. J Am Soc Nephrol. 2014; 25(5):967-77. PMC: 4005304. DOI: 10.1681/ASN.2013060611. View

11.

Hennigan S, Kavanaugh A . Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2009; 4(4):767-75. PMC: 2621374. DOI: 10.2147/tcrm.s3470. View

12.

Vignais M, Sadowski H, Watling D, ROGERS N, Gilman M . Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol. 1996; 16(4):1759-69. PMC: 231162. DOI: 10.1128/MCB.16.4.1759. View

13.

Gu L, Dai Y, Xu J, Mallipattu S, Kaufman L, Klotman P . Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy. AIDS. 2013; 27(7):1091-8. PMC: 3918880. DOI: 10.1097/QAD.0b013e32835f1ea1. View

14.

Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L . Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018; 128(12):5479-5488. PMC: 6264739. DOI: 10.1172/JCI120156. View

15.

Xie Y, Kole S, Precht P, Pazin M, Bernier M . S-glutathionylation impairs signal transducer and activator of transcription 3 activation and signaling. Endocrinology. 2008; 150(3):1122-31. PMC: 2654735. DOI: 10.1210/en.2008-1241. View

16.

Hu Y, Hong Y, Xu Y, Liu P, Guo D, Chen Y . Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC. Apoptosis. 2014; 19(11):1627-36. DOI: 10.1007/s10495-014-1030-z. View

17.

Smolen J, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E . Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371(9617):987-97. DOI: 10.1016/S0140-6736(08)60453-5. View

18.

Viau A, Karoui K, Laouari D, Burtin M, Nguyen C, Mori K . Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest. 2010; 120(11):4065-76. PMC: 2964970. DOI: 10.1172/JCI42004. View

19.

Zhong Z, Wen Z, Darnell Jr J . Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994; 264(5155):95-8. DOI: 10.1126/science.8140422. View

20.

Zhang L, Xu X, Yang R, Chen J, Wang S, Yang J . Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling. Drug Des Devel Ther. 2015; 9:2139-48. PMC: 4404961. DOI: 10.2147/DDDT.S81390. View